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UNCERTAINTY ON RADIATION DOSES ESTIMATED BY 
BIOLOGICAL AND RETROSPECTIVE PHYSICAL METHODS  
Elizabeth A. Ainsbury, Daniel Samaga, Sara Della Monaca, Maurizio Marrale, Celine Bassinet, Christopher I. 
Burbidge, Virgilio Correcher, Michael Discher, Jonathan Eakins, Paola Fattibene, İnci Güçlü, Eva Lund, Nadica 
Maltar-Strmečki, Steve McKeever, Christopher L. Rääf, Sergey Sholom, Ivan Veronese, Albrecht Wieser, 
Clemens Woda and Francois Trompier. 
Biological and physical retrospective dosimetry are recognised as key techniques to provide individual estimates of dose 
following accidental or unexpected exposures to ionising radiation. Whilst there has been a relatively large amount of 
recent development in the biological and physical procedures, statistical development of uncertainty analysis techniques 
has in many areas failed to keep pace. The aim of this paper is to review the current state of the art in uncertainty 
analysis techniques across the EURADOS Working Group 10 – Retrospective dosimetry partners, to give concrete 
examples of implementation of the techniques recommended in the international standards, and to further promote the 
use of Monte Carlo techniques to support characterization of uncertainties. It is concluded that sufficient techniques are 
available and in use by most laboratories for acute, whole body exposures to highly penetrating radiation, but that 
further work will be required to ensure that the standards are adequately applied for the more complex exposure 
scenarios. 
INTRODUCTION 
In Europe today, and indeed the whole world, the 
current state of the art of retrospective radiation 
dosimetry incorporates a number of key biological and 
physical retrospective techniques. Amongst the 
biological methods, the dicentric chromosome assay 
(DCA), which relies on the relationship between the 
frequency of dicentric chromosomes in peripheral 
blood lymphocytes and the absorbed dose (“dose”) of 
exposed persons, is recognised to be the most well-
developed of these1,2. The cytokinesis-blocked 
micronucleus (CBMN) assay is also regarded as an 
important tool for biological assessment of radiation 
dose and is growing in importance3. For longer-term 
retrospective dosimetry, fluorescence in situ 
hybridization (FISH) staining of translocations can be 
used4. In addition, new techniques for premature 
chromosome condensation and scoring offer alternative 
methodologies5 and the γ-H2AX assay allows direct 
measurement of double-strand breaks (DSB), which are 
caused almost exclusively by ionising radiation, in a 
human cell6. For physical dosimetry7, the key 
techniques are electron paramagnetic resonance (EPR) 
with bone8, teeth9, nails10,11,12 and glass13 and optically 
or thermally stimulated luminescence (OSL/TL), 
chiefly of electronic components in mobile phones14. A 
large number of studies have demonstrated the need for 
a wider range of techniques, both separately and in 
collaboration, in order that dosimetry can be carried out 
in several potential exposure scenarios15,16. Most 
importantly, the operational assays have recently been 
amalgamated into fully functional emergency response 
plans through the network: Realising the European 
network of biodosimetry, RENEB16,17. 
The European Radiation Dosimetry Group 
(EURADOS) was set up to advance the scientific 
understanding and the technical development of the 
dosimetry of ionising radiation by the stimulation of 
collaboration between laboratories in Europe. As part 
of the network, EURADOS Working Group 10 
(WG10) was formed, with the objective of establishing 
a network of European (and some non-European) 
laboratories with expertise in the area of physical and 
biological retrospective dosimetry. The aims of WG10 
include: establishing a multi-parameter approach to 
dose assessment in retrospective dosimetry (including 
emergency response); evaluating newly developed 
dosimetry methods; and establishing a common 
approach for uncertainty estimation throughout 
biological and physical methods of dosimetry. In order 
to address this last point, EURADOS WG10 task group 
10.6 was created, with a focus on uncertainties 
associated with retrospective dosimetry techniques.  
Uncertainty analysis can be defined as the method to 
quantify the degree of confidence considering the 
model outputs taking into account the model inputs 
(data and parameters)18. In classical statistics, the aim 
of uncertainty assessment is to provide a range around 
the estimated quantity, the uncertainty interval, within 
which the real value of the variable is likely. The 
uncertainty interval usuallydepends on the standard 
deviation that corresponds to the uncertainty associated 
with the estimate of the variable. The process of 
uncertainty assessment is an intrinsic part of any 
method of retrospective radiation dosimetry, however, 
it has previously been noted that estimation approaches 
vary between different dosimetry techniques and, 
furthermore, that the overall effort devoted to 
uncertainty analysis varies widely between groups of 
retrospective dosimetry practitioners19,20. The Guide to 
the Expression of Uncertainty in Measurement (GUM) 
is the standard reference for uncertainty analysis 
techniques, and most of the retrospective dosimetry 
laboratories across Europe and the world use the GUM 
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uncertainty estimation techniques21. There are several 
relevant ISO standards and guides to assist with 
implementation of GUM22,23 and the associated 
analysis techniques, e.g. for assessment of accuracy24 
and laboratory intercomparisons25.  
There are also a number of alternative techniques 
that may be employed, both for measurement and 
calculation of the quantity of interest, i.e. absorbed 
dose, for the propagation of uncertainties through this 
calculation, and for quantification of both type A 
(generally corresponding to random) and type B 
(generally systematic) uncertainty estimates. For 
example, Monte Carlo simulation, which includes auto- 
and cross-correlations among the components, can be a 
convenient means of obtaining probability distributions 
for parameter estimation in non-linear systems26,27. 
This can be combined with the use of Bayesian logical 
constructs to constrain parameter estimation to help 
improve the accuracy of dose estimates28. Bayesian 
statistics considers the uncertain parameters and 
variables at random (probabilistic variables). The 
analysis takes into account assumed prior distributions 
for each parameter (which must be chosen by the user), 
together with the experimental data to produce a 
subsequent probability density function (pdf) that 
describes the probability of the observations. In all 
cases, the appropriateness of the approach should be 
carefully evaluated29.  
The aims of EURADOS WG10 task 10.6 are thus to 
survey the different methods used to assess 
uncertainties in retrospective techniques, to compare 
and contrast the different approaches, to popularise the 
potential of Monte Carlo or Bayesian techniques, to 
identify best practice and finally to attempt to 
homogenise the approaches where possible and/or 
desirable. The survey of uncertainty assessment 
methods used by WG10 participants was carried out in 
2012. The survey participants were overwhelmingly 
supportive of the need for a review of uncertainty 
analysis techniques, inter- and intra-technique 
comparisons of methods, and organization of centrally 
administrated training once best practice has been 
identified.  
In this publication, the authors present a comparison 
of techniques of uncertainty estimation amongst 
laboratories using biological and physical retrospective 
dosimetry methods of dicentric chromosome, 
micronucleus, PCC, FISH translocation and γ-H2AX 
analysis, EPR, OSL and TL. The data were collated 
from the survey and discussions at EURADOS annual 
meetings 2012 – 2016 and from results of the RENEB 
networking project17. The similarities and differences 
in recommended uncertainty analysis methods, those 
used in practise, and also the experimental and external 
factors that influence the results, are discussed. In 
biological dosimetry, Bayesian analysis methods have 
so far only been implemented for the DCA30 and thus 
are discussed in this context. Bayesian approaches have 
been developed for application in luminescence 
retrospective dosimetry per se28, and others are widely 
used to compare retrospective archaeological and 
geological age estimates31, but have not yet been 
applied for accident reconstruction. The wider 
applications of Monte Carlo sampling are also 
discussed, with the aim of promoting the techniques for 
use within the community. Finally, areas in which 
biological and physical retrospective dosimetry 
uncertainty analysis methods may be improved are 
considered. 
DOSIMETRY METHODS 
There are a number of relevant publications including 
recent reviews of biological and physical retrospective 
dosimetry methods, thus we here only present a 
relatively high level summary in order to set the scene 
for the review of the uncertainty estimation methods 
that are currently in use. 
Biodosimetry 
The most well-established assays for biological 
dosimetry rely on assessing chromosome aberrations in 
peripheral blood lymphocytes. The rationale behind 
counting aberrations is that the number of aberrations 
induced by ionising radiation corresponds to the 
absorbed dose. The established techniques are: (1) the 
dicentric chromosome assay (DCA, which is the “gold 
standard”2; (2) Fluorescence in situ hybridization 
(FISH)4; (3) Premature chromosome condensation 
(PCC)5; (4) cytokinesis-block micronucleus assay 
(CBMN)3, and (5) counting of γ-H2AX foci which 
form at the site of double strand breaks6. 
The two main prerequisites for biodosimetry are the 
stability of aberrations with time following irradiation 
and knowledge of the background level, i.e. the number 
of aberrations in a given sample before irradiation 
occurred. DCA, PCC and CBMN show stability of 
responses for several months, as induction of these 
aberrations means the cells cannot reproduce and thus 
the cells die and these aberrations are gradually 
removed from the population of circulating 
lymphocytes, Therefore, the relative specificity to 
ionising radiation drives the accuracy of these methods. 
In contrast, γ-H2AX and FISH are not radiation 
specific, however, the individual background levels are 
becoming more well understood4,6,32. The vast majority 
of γ-H2AX aberrations disappear within approximately 
24 hours and thus this is very much a short term assay, 
however, translocations detected by FISH are stable 
over many years. All of the established methods were 
developed based on visual scoring techniques, and a 
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large amount of work has been required to ensure their 
suitability for mass casualty events17. The current status 
is promising although the need for automation and 
other more rapid strategies remains1,33,34 and there is 
also a need for development of appropriate, reliable, 
uncertainty methods.  
Dicentric chromosome assay 
As the “gold standard” of biodosimetry, the statistical 
analysis methods for the dicentric chromosome assay 
(DCA) are extremely well defined. An ISO standard 
has been created for the assay in routine35 and rapid 
assessment “triage”36 modes. The assay’s standardised 
guidance text, the International Atomic Energy 
Authority (IAEA) cytogenetics manual1, is used by 
almost all practitioners of the assay for biodosimetry 
purposes.  
In brief, the dicentric yield y (average number of 
dicentric chromosomes per cell) is modelled as a 
function of the absorbed dose D by formation of a 
linear or linear-quadratic calibration curve: 
 
                (1) 
 
The specific type (energy/LET) of radiation determines 
the type of curve, which is created by counting 
(scoring) aberrations in large numbers of cells, 
especially at low doses. For in vivo exposure cases, the 
yield of aberrations observed in the exposed sample is 
then compared to the calibration curve. Dicentrics are 
highly specific to ionising radiation, with only a few 
rarely used radiomimetic drugs able to induce them, 
thus, the lower limit of detection is approximately 100 
mGy1. Simple methods also exist to account for 
fractionation or partial-body exposures, chiefly based 
on adherence to or departure from the expected Poisson 
distribution of aberrations1.  
Micronucleus assay 
The in vitro cytokinesis-block micronucleus assay 
(CBMN) is another well-established method for 
biodosimetry3. The assay is based on assessing the 
frequency of acentric chromosome fragments 
(micronuclei, MN) and a small extent malsegregation 
of whole chromosomes in binucleated (BN) cells. MN 
are also caused by many clastogenic and aneugenic 
agents37 and thus are not specific for ionising radiation. 
Compared to the DCA, scoring of MN is simple and 
quick. Furthermore, scoring can be automated and 
international standardization is in place38.  
The reported background frequency of MN is 
variable: values ranging from 0 to 40 per 1000 BN 
have been recorded1. Consequently, the lower limit for 
dose detection by conventional CBMN is 0.2 - 0.3 Gy; 
although more detailed analysis restricted to 
centromere positive cells lowers this limit to 0.05 - 0.1 
Gy. The most important influencing factors of MN 
background are dietary factors, exposure to 
environmental clastogens and aneugens, age and 
gender1. When possible, for instance for medical 
exposure scenarios, the variability of the background 
level should be decoupled from the other parameters by 
identification of the individual background level in 
blood samples taken before irradiation39. 
Dose estimation using CBMN follows the same 
strategy as for the DCA. The absorbed dose can be 
assessed up to few months after exposure1,40,41. A 
drawback of CBMN is the natural overdispersion of 
MN data, therefore partial-body irradiation is hard to 
detect, and also the larger variation in background 
levels which means that the detection limit is generally 
greater37. 
PCC 
An important limitation of the DCA, CBMN and FISH 
assays is the prerequisite for lymphocytes to enter the 
mitotic phase, which requires culturing for 48 hours or 
more. Thus dose estimates always take several days. 
The need for metaphases induces several technical 
problems including radiation induced mitotic delay and 
cell death that can lead to non-representative cell 
samples. After high doses of ionising radiation, this can 
cause considerable underestimation of absorbed doses. 
Premature Chromosome Condensation (PCC) can be 
induced by cell fusion or chemical induction. The cell 
fusion PCC technique visualises chromosome 
aberrations in the interphase cells, which can allow 
same day biological dose assessment. Chemically 
induced PCC has been validated for triage following in 
several potential exposure scenarios1,5,40. 
PCC analysis is not a biomarker on its own, rather it 
should be combined with scoring of specific 
chromosome aberrations (e.g. fragments, rings or 
translocations). The frequency of spontaneous 
occurring PCC fragments is in the range of the 
dicentric frequency, 1 to 3 in 1000 cells.  
For dose assessment with PCC, the same tools are 
used as presented for the DCA. PCC assay is 
particularly useful for assessment of a wide range of 
doses. It is applicable as well to exposure at low doses 
(as low as 0.2 Gy for PCC fragments) as to life-
threatening high acute doses of low and high-LET 
radiations (up to 20 Gy)42. 
Fluorescence in situ hybridization 
Dicentric chromosomes, rings and MN are “unstable” 
chromosome aberrations and thus they vanish from 
peripheral blood lymphocytes pool at the rate that cell 
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renewal occurs. Fluorescence in situ hybridization 
(FISH) techniques allow identification of stable 
translocations, and have been used for many years for 
assessment of past exposures1,43.  
However, background frequencies increase 
significantly with age and vary greatly between 
individuals of the same age and dose history. No 
significant gender effects have been observed but 
smoking habit has been suggested to be of 
significance32.  
The observed number of aberrations must be 
corrected for these known confounding factors in order 
to obtain radiation-induced translocations only, before 
dose response curves are calculated as for dicentrics1. 
Note that as a consequence of stability and non-
specificity to radiation, the minimum detectable dose is 
limited as a function of time: in the region of 1.8 mGy 
per year (20 - 69 years) for acute doses, and for chronic 
exposure 15.9 mGy per year respectively42. At high 
doses, correlation of translocations and complex 
aberrations in cells is also of importance1. Although the 
biological complexity of this assay is relatively well 
understood, the uncertainty analysis techniques remain 
simplistic and more work is needed. 
γ-H2AX 
The γ-H2AX assay, commonly used for investigating 
radiosensitivity, has in recent years become a well–
established biomarker for radiation induced DNA 
double-strand breaks and thus radiation exposure6,44. 
Fluorescence microscopy or flow cytometry measure 
the formation of DNA repair-protein clusters called γ-
H2AX foci (in terms of number or intensity 
respectively) in peripheral blood lymphocytes of 
exposed persons45,46. The foci are not specific for 
radiation exposure and spontaneous frequency is very 
low. Wide use for biodosimetry purposes is limited by 
fast loss of the signal (maximal γ-H2AX level is 
reached 30 min after irradiation, tissue related the half-
life of the signal is 2h - 7h) as well as high individual 
variability42,47,48.  
Advantages of the assay are its high sensitivity and 
relatively low detection limit (as low as tens of mGy), 
the need of only a few drops of blood, absence of 
required lymphocyte cultures and the ease of 
automation. However, the absorbed dose can only be 
assessed up to approximately 1 day after exposure49. In 
addition, the influence of factors such as age, gender 
and genotypes are not yet well understood50–56. The 
relatively large uncertainties allow γ-H2AX to be used 
for biodosimetry only in extremely controlled 
scenarios57 and uncertainty assessment is carried out on 
a case-by-case basis, with the sophistication of the 
analysis varying greatly between laboratories. 
Physical retrospective dosimetry 
For the purposes of retrospective dosimetry, physical 
dosimetry methods are retrospective dose estimation 
techniques based on the quantitative evaluation of 
detectable changes induced by ionising radiation in 
inert materials or by the activation of atoms such as 
sodium or phosphorus when exposed to neutrons. They 
are usually only suitable for detection of external 
exposure and for situations of partial or localised 
exposure, they provide a useful dosimetric information 
only if the “fortuitous dosemeter” (defined as a 
material validated for dosimetry which the individual 
happens to be carrying) is by chance within the 
radiation field.  
The three physical dosimetry techniques considered 
in this review are the Electron Paramagnetic Resonance 
(EPR), the Optically Stimulated Luminescence (OSL) 
and the Thermoluminescence (TL).  
Electron paramagnetic resonance 
EPR dosimetry is based on the quantification of 
paramagnetic species (defects or free radicals) induced 
by ionising radiation. In solids, as crystalline materials, 
the radicals/defects can be trapped and are thus 
generally sufficiently stable to be measured. The EPR 
signal is a measure of the radical/defect concentration 
within the solid matrix and is usually proportional to 
the mean absorbed dose in the sample. The principle of 
EPR spectroscopy may be found in several textbooks58–
60 and a detailed description of applications in 
retrospective dosimetry is given by Trompier and 
colleagues61. In general, depending on the complexity 
of the EPR spectra, the area under the absorption curve 
or peak-to-peak amplitude of an EPR signal are used 
and considered to be proportional to the concentration 
of paramagnetic species.  
The validated assays for retrospective analysis are 
calcified tissues (tooth enamel and bone) and sugar, 
while materials such as nails, mineral glass, 
sweeteners, plastics and clothing fabrics that are 
widespread among humans are under 
investigation12,13,62–66. The ideal characteristics of a 
beneficial fortuitous dosemeter are a high radiation-
induced signal yield, the absence of endogenous 
signals, a low UV-induced signal, low detection limit, 
the linearity of the signal with dose and post-irradiation 
signal stability61. The quantity of the radiation-induced 
radicals may be correlated to a value of the absorbed 
dose either via application of a “positive control” - the 
delivery of additional radiation doses with a laboratory 
source (“additive dose” method) or via a calibration 
curve. Calibration curves may be created on an 
individual basis for each sample, or using different 
samples each irradiated at a different radiation dose, 
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i.e. always applying the same sample-specific, signal-
to-dose calibration curve. A disadvantage of the 
universal calibration curve is that it does not take into 
account the specific sensitivity of the sample. The 
curve is built using the average of the sensitivities of 
different samples. This of course affects the uncertainty 
associated with the estimated dose.  
When EPR is used for ionising radiation dosimetry, 
other confounding factors such as UV exposure or 
mechanical stress may generate additional radicals 
whose signals may overlap or mask the radiation-
induced signal. In these cases, spectral simulations or 
other numerical analysis methods are needed, in order 
to decompose the different components of the spectrum 
and extract the signal of interest.  
The average lifetimes for the radicals vary from 
minutes to billions of years. Controlling the sample 
storage condition, for example by keeping the samples 
in dark, low humidity and sometimes in a freezer, will 
save the samples from unwanted changes.  
A key advantage of EPR analysis is that it can be 
repeated as many times as needed, as the readout 
process does not alter the signal. This gives the 
possibility to estimate the effect of sample positioning, 
spectrometer reproducibility and stability which all 
play a large role in the uncertainty budget for EPR dose 
estimates. 
Optically/thermally stimulated luminescence 
Luminescence dosimetry relies on the stimulated 
emission of light from an insulator or a semiconductor 
after the absorption of energy from ionising radiation67. 
Ionising radiation transfers energy to the electrons of 
the solid, moving them to a metastable state. When the 
electrons return to the ground state, recombination 
occurs and luminescence light is emitted. This 
recombination occurs after absorption of stimulation 
energy provided by heat in the case of 
Thermoluminescence (TL) and by light for Optically 
Stimulated Luminescence (OSL).  
Crystals contain defects, which produce spatially 
localised energy levels in the energetically “forbidden” 
zone between the valance and conduction bands. 
Ionising radiation produces electron-hole pairs by 
exciting electrons beyond the potential of their parent 
molecule into a delocalised state, which is most 
commonly the conduction band. As electrons and holes 
migrate in the conduction and valence bands, most 
recombine rapidly but some become trapped in 
metastable states associated with the defects. Later, 
these can be excited by thermal or optical stimulation, 
so that electrons and holes are again able to recombine. 
Following recombination, the host molecule is excited, 
and some emit photons at visible wavelengths as they 
de-excite: this emission is termed thermally or optically 
stimulated luminescence, depending on the type of 
stimulation. 
In TL, the light yield is recorded as a glow curve, i.e. 
as a function of the stimulating temperature, whereas in 
OSL the number of emitted photons per time interval is 
recorded as a function of the optical stimulation time. 
For both stimulation modes, the area under the glow 
curve / OSL decay curve is related to the total number 
of emitted photons and thus to the absorbed dose in the 
dosemeter.  
Published results on the applications of TL and OSL 
for retrospective dosimetry have concentrated on OSL 
and TL techniques on chip cards, electronic 
components and glass from personal electronic 
devices68. For some of these methods, interlaboratory 
comparisons have been performed69. 
UNCERTAINTY ESTIMATION APPROACHES 
Biological dosimetry – dicentric assay 
Frequentist approach: Confidence limits  
Uncertainty assessment for cytogenetic dosimetry is 
widely understood as the quantification of the 
variability within the dosimetric model, e.g. as defined 
by equation (1). Thus, parameter uncertainties as well 
as biomarker variability need to be considered. Indeed, 
full uncertainty analysis for cytogenetic dosimetry 
following the GUM21 considers a long list of factors. 
For routine dosimetry, this list includes: the type and 
parameters of the dose response curve, the stochastic 
characteristics of the biological marker, inter- and 
intra-individual variability, technical noise sources and 
practical limitations (e.g. in vitro calibrated methods 
applied to in vivo data). More complex scenarios of 
exposure induce further challenges, as described by 
Vinnikov and colleagues19,70. As processing is time 
consuming and the level of experience varies between 
laboratories, the potential for standardization and 
verification of uncertainty analysis methods is very 
limited. This may explain the absence of agreement on 
some of the expected uncertainty parameters within 
this field, such as the coverage factor21.  
For the DCA, which has the most well developed set 
of uncertainty estimation methods of all the biological 
assays, uncertainties of estimated doses are generally 
assessed by the analysis of the variability of the 
dicentric yield y and the parameters of the calibration 
curve C, α, and β71–74, according to the GUM 
methodology21 (with detailed examples for several of 
the biological techniques given75). In the version of the 
IAEA manual published in 2001, which was the first 
time uncertainty analysis was discussed in detail in a 
methodological biodosimetry publication, three 
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methods of uncertainty assessment were presented, 
labelled A - C. It was reasoned that Merkle’s Approach 
“C”72 performs best for low numbers of dicentrics (as 
in low doses and/or few cells), whereas for high doses 
Savage’s Approach “A”71 is more precise. In the 
updated 2011 version of the IAEA manual1, Merkle’s 
approach is discussed in greater detail. This method of 
uncertainty assessment allows incorporation of both the 
Poisson error of the yield as well as errors in the dose 
response curve parameters. The confidence bands of 
the calibration curve follow from the insight that the 
maximum likelihood estimate of the parameter vector 
is asymptotically multivariate normal72. The upper 













2 denotes the variance of x and sx,z the 
covariance of x and z, for each value of x and z in the 
equation. The regression factor R2 gives the range 
within which the true average yield is to be expected. 
This is equivalent to the confidence limit of the Chi-
squared distribution with 2 or 3 degrees of freedom for 
linear or linear-quadratic fits; i.e. for 95% confidence 
intervals, R = 2.45 at 2 degrees of freedom (df) and R = 
2.80 at df = 3, respectively.  
Finally, the calculation of confidence intervals for 
the estimated dose includes two steps:  
(1) Determination of the boundaries YU and YL of the 
dicentric yields which are consistent with the 
observed yield in the sample (95% confidence 
limits for the mean parameter of a Poisson random 
number). 
(2) Determination of the absorbed dose for which the 
upper dose response curve yul exceeds YL and the 
dose where the lower curve yll exceeds YU. 
Note that some authors reason that the combination of 
95% confidence intervals for the dicentric yield as well 
as for the confidence bands leads to a falsely large 
confidence interval for the dose, thus in case of 
combined errors 83% confidence limits of the Chi-
squared distribution are more appropriate76,77 (the 
square root of the regression factor at 1-α = 83% is R = 
1.88 (df = 2) and R = 2.24 (df = 3) respectively). 
The alternative approaches given in the IAEA 
manual: A (Savage71) and B (again Merkle72), are built 
on classical error propagation calculations for normally 
distributed random variables. They apply the Delta 
method to calculate the standard error for the estimated 
dose from the calibration curve and its parameter 
uncertainties. 
For dose estimations in more complicated scenarios, 
extensions exist including correction for protracted or 
fractioned doses and partial-body exposures. In these 
cases, in principal, after correction of the curve, 
uncertainty assessment follows the same strategy as 
above. However, in this case, either the simplified 
method C described above is used (with no parameter 
uncertainties) or equation (2) must be adjusted 
manually. Tools to apply the standard (IAEA) methods 
for automated dose estimation and uncertainty 
assessment are available, including CABAS 
(Chromosomal ABerration Calculation Software)78 and 
DoseEstimate79. 
In order to assess inhomogeneous exposures more 
realistically, Sasaki modelled the damaged cell 
population with a mixed Poisson, which can be 
numerically deconvoluted80. The resulting exposure 
profile indicates some uncertainty within the dose. 
However, this does not represent a rigorous uncertainty 
assessment.  
In addition, a correction factor for confidence 
intervals of overdispersed data (i.e. dispersion index 
σ2/y > 1) is proposed1. For those samples, the limits of 
the expected range of the yield, YU and YL, of a sample 
with mean y and variance σ2 should be adjusted as 
follows (with either YU and YL as appropriate):  
 
    
        





     (3) 
Probabilistic Approach: Bayesian methods 
In parallel to the classical, frequentist approach, 
Bayesian methods are becoming increasingly 
popular30,81,82. Key to the Bayesian concept is the 
application of the inversion theorem in its continious 
version, i.e.: 
 
          
             





where D denotes the unknown parameter (absorbed 
dose) and Xobs the observation (the dicentric yield 
within the sample, y, and the calibration data). Thus, 
the posterior dose distribution (or calibrative dose 
density), P(D|Xobs), scales with the product of the 
likelihood (or predictive density) P(Xobs|D) and the 
prior P(D):  
 
P(D|Xobs) ∝ P(Xobs|D)P(D)   (5) 
 
With respect to uncertainty analysis, the Bayesian 
approach does not require additional considerations, 
since the resulting distribution P(D|Xobs) (probability 
for a dose given the data) inherently provides 
quantification of the uncertainty within the dosimetric 
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model. Consequently, Bayesian uncertainty intervals 
for the calibration parameter (the dose in this case) are 
accurate. 
Apart from the intrinsic inclusion of uncertainty 
within the posterior model, the greatest advantage 
compared to the frequentist approach is the possibility 
to include other information besides the number of 
aberrations through the chosen prior distribution(s). 
The choice of the prior could be sensitive, since well 
chosen, informative priors should guide noisy data 
towards the true dose, whereas incorrect priors may 
drive the estimate away from the true dose. Some 
authors reason that high quality prior information is 
almost always available, and thus Bayesian approaches 
are more appropriate for biological dosimetry70,81. 
Higueras and colleagues30 also showed that if an 
appropriate prior is sensely determined, the actual 
choice of prior in fact doesn’t greatly impact the 
overall dose assessment in some scenarios.  
In contrast to the frequentist approach, which relies 
on processing the information successively from the 
initial sample, to the calibration data, to a point 
estimate of the dose surrounded by a confidence 
interval; the Bayesian approach incorporates all 
decisions at the same time and the resulting equation is 
then analytically, numerically or empirically solved for 
the required components. A fully Bayesian method 
thereby also adjusts the probability density function of 
the aberrations to the specific scenario of exposure and 
simultaneously incorporates the uncertainties of the 
parameters of the dose response curve. The 
mathematical complexity of this task means that it is 
not possible to define a general Bayesian solution 
applicable to all exposure scenarios.  
Nevertheless, Di Giorgio and Zaretzky showed a 
procedure to include prior information in dose 
estimation in a Bayes-like manner83. Discretization of 
the dose range and a separated frequentist estimation of 
response curve parameters provides a straightforward 
method resulting in a Bayes-like posterior of the 
dose83. Note that this example also illustrates the 
influence of the prior on the credible intervals for the 
dose. 
For Bayesian uncertainty assessment of the dose, 
three types of solutions can be identified from within 
the literature. Firstly, analytical expressions for 
simplified scenarios: The earliest prominent example of 
such a solution is the calibrative density for a Poisson 
distributed number of aberrations linked to the 
absorbed dose via a linear dose response without 
intercept (C = β = 0) using Gamma priors for dose and 
slope84. In this case, an analytical expression is derived 
that is proportional to the posterior. The authors 
reasoned that the trivial dose response curve is 
appropriate for neutrons (high LET) at high doses, 
however, neutrons are known to imply 
overdispersion85. Brame and Groer revisited the same 
scenario in 2002, replacing the Poisson distribution by 
a negative binomial in order to jointly model the 
density of the slope and the degree of overdispersion82. 
Secondly, practical guides for specific scenarios that 
provide R code for reuse. Higueras et al.39 discussed 
the reasonable set up of Poisson and compound Poisson 
models (Neyman A, negative binomial, Hermite) for 
biodosimetry. Complete and simplified models are 
provided and three examples are given for dose 
assessments for a linear quadratic calibration curve 
(two Poisson and one negative binomial regression 
model). For each example three different priors are 
compared39. Together with Vinnikov, the same group 
of authors presented a guide for analysis of partial-
body exposure for a zero-inflated Poisson model30. 
This guide approximates credible intervals for the 
irradiated fraction of the body and the received dose 
simultaneously from:  
 
           
∝    
 
 
    






   
          
      
                       
(6) 
 
where D is the absorbed dose, F the fraction of 
irradiated body, d0 the 37% cell survival dose, n 
number of cells in patient data, n0 the number of cells 
without aberrations, and Xi is a negative binomial 
distributed random number corresponding to the 
unirradiated fraction of the cells whose mean and 
variance depends on the index i and the mean and the 
variance of the calibration curve respectively. Uniform 
priors for F and d0 and a Gamma prior for the dose are 
used30. 
Thirdly, Software packages: The Java application 
CytoBayesJ for cytogenetic radiation dosimetry81 and 
R package radir containing the models by Higueras86 
offer platform independent software solutions to 
Bayesian uncertainty assessment. CytoBayes offers 
tools for (i) distribution testing (compound Poisson 
models), (ii) posterior calculations of the number of 
aberrations (several combinations of priors and yield 
models), (iii) Bayesian-like dose assessment (Poisson 
data), (iv) full Bayesian calculation of posteriors of the 
dose (Poisson data in y = αD), as well as (v) Bayesian 
methods for detection limits81. In order to simplify the 
analysis, most scenarios include a Bayesian uncertainty 
assessment of the dicentric yield and then make a 
conventional frequentist inverse regression step due to 
mathematical complexity. 
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Ultimately, it can be concluded that the Bayesian 
methodology provides the most coherent approach, but 
at the same time it is far more technically challenging 
than the dose and uncertainty assessment methods 
currently recommended and used by most 
practitioners1. Despite recent developments, such 
methods thus remain to date an “expert” tool. 
Therefore, software solutions such as those described 
above will be required to bridge the gap between the 
necessary mathematical skills and the users. In 
particular, the potential pitfall of incorrectly chosen 
priors will need careful consideration going forward, 
since the methodological coherence of prior and 
posterior can be seen conceptually as a self-fulfilling 
prophecy that masks unexpected results. 
EPR 
Sources of uncertainty 
Uncertainties or “errors” can be classified into two 
types: type A errors can be evaluated by statistical 
methods whereas type B errors are commonly termed 
“systematic errors” and must be dealt with by other 
means. Historically uncertainties have also been 
classified as “random” or “systematic” errors, and these 
terms are still sometimes used for type A and B errors, 
respectively. However, it is important to note that the 
GUM recommends the nomenclature of “type A” or 
“type B” to classify how an error is dealt with rather 
than where it originates21.  
For EPR, determination of irradiation doses 
retrospectively is not a straightforward task. 
Uncertainties both of type A and of type B are 
introduced and must be carefully analysed and 
reported. Several technical publications have been 
produced, dedicated to the determination of 
uncertainties with EPR spectroscopy on materials such 
as tooth enamel or alanine87–90. A list of possible 
sources of uncertainties has been drafted for tooth 
enamel dosimetry in Fattibene and Callens91 and many 
issues considered in the list (effect of sample 
anisotropy, parameters of spectrum acquisition, 
spectrometer instability, sample mass, spectrum 
processing methods, uncertainty linked to the dose 
calibration curve, etc.) are valid for almost all the EPR 
dosimetry methods. As recommended by IAEA87, the 
total combined uncertainty is expressed as the 
quadratic sum of the possible source of uncertainties, 
under the assumption that these sources are 
uncorrelated. Specifically,: 
 22222 TCESFED     (7)            
where σF is the contribution from the fading 
correction; σS is the contribution from the sample 
preparation; σE the contribution from the EPR 
measurement; σT the contribution from the numerical 
treatment of spectra, and σC is the contribution from the 
calibration of EPR dose response, including differences 
in radiation sensitivity. 
The fading contribution depends on the detector 
materials used in analysis. For tooth enamel it can be 
assumed that σF doesn’t contribute to the overall 
uncertainty87, however, a sufficient delay should be 
observed after irradiation for signal stabilization due to 
recombination of short-lived species. A minimum 
delay of 48 hours is usually recommended for calcified 
tissue. This recommendation is also valid for most 
irradiated materials including sugars, for example, for 
which the stabilization delay can reach weeks92.  
EPR dosimetry is usually not performed on unstable 
species. Nevertheless, a few groups are considering the 
use of the unstable signal component in nails for 
dosimetry application10,11,93. In this case, the fading 
correction may significantly contribute to the 
uncertainty budget, because of the influence of multiple 
parameters (temperature humidity, light, etc.) which 
may be difficult to evaluate for the delay between 
irradiation and sample harvest. In addition, special 
attention must be paid to control fading during the 
storage period or at least the parameters of influence. 
Similarly, the sample preparation approach depends on 
the material used as well as on the method chosen. 
The other three factors affecting the total uncertainty 
stem from measurements and data processing. The EPR 
measurement uncertainty, σE, depends on a complex 
combination of uncertainties linked to the performance 
of EPR spectrometers per se and the experimental set-
up. Uncertainty contributions from the numerical 
treatment of spectra, σT, and contributions from the 
calibration of EPR dose response, σC, can be minimised 
through experimental validation of the method for 
different materials as has been done for tooth enamel91 
and smart phone touch screen glass13. For this reason, 
international interlaboratory comparisons of EPR dose 
reconstruction are the most useful tools for identifying 
contributing sources of uncertainties and finding the 
best solution to minimise these. 
Evaluation of uncertainties 
The uncertainty analysis approach used by several 
EURADOS partners is the standard one recommended 
for uncertainty estimation for EPR on alanine. In brief, 
this method consists of taking the mean value of 
multiple measurements as the best evaluation of the 
true value and the sample standard deviation as the 
uncertainty on the signal. A minimum of ten 
measurements is commonly used; however, some 
EURADOS WG10 members who completed the survey 
regularly perform 12 or 16 measurements (3 
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dosemeters in 4 different orientations or 4 dosemeters 
in 4 orientations). In order to measure unknown 
absorbed doses, a calibration curve is required to be 
created to describe the relationship between EPR signal 
(y) and dose (D): y=F(D). The parameters of the 
function, F, are estimated through a best-fit procedure. 
The dose-signal relation is usually linear and weighted 
regression is sometimes, but not always, applied. Thus, 
the general expression of the estimated dose ED as a 




where a is the calibration curve slope and b is the y-
axis offset. The combined variance u2(ED) consists of 
the variance in the measured signals u2(y), the variance 
in the y-axis offset u2(b), the variance in the slope in 
the calibration curve u2(a), the covariance of b and a 
and finally the dose dependent variance in the doses 
given to the calibration samples, u2cal. The covariance 
term was found to be negligible in accurate EPR 
dosimetry94,95 and it is assumed that this will be the 
case for retrospective dosimetry. 
An unbiased estimate of the variance of the 















)(                         (9) 
 
where Dk are the known absorbed doses given to the 
calibration samples, yk are the corresponding signal 
values and bk is in this case the zero dose for each 
calibration sample. The denominator represents the 
number of calibration points minus the two degrees of 
freedom. 







































22 )()(     (12) 
and the covariance term is omitted. 
 
These principals allow deduction of chiefly type A 
uncertainties. Type B uncertainties are generally 
considered by taking into account uncertainties in 
fading, corrections for radiation energy, environmental 
factors, spectrometer variations and calibration dose. 
Note, however, that fading could be treated as a type A 
uncertainty if multiple measurements of dispersion in 
fading for a given time period – such a method is used 
for TL/OSL dosimetry, as described in the next section. 
An alternative approach relies on determination of 
the absorbed dose in alanine measurements from the 
calibration curve, by relating the amplitude of the 
EPR signal to absorbed dose. To estimate the 
uncertainty of dose, u(ED), an imperfect 
calibration curve is designed and the procedure 
described by Nagy89 is applied; in the case of a 
calibration plot based on n calibration points, the 
confidence interval for the dose value D, determined 
from m replicate measurements of the signal of a test 




























where: tn-2,P is the Student coefficient for the chosen 
probability P; sfit is the standard uncertainty of the 
mean of the fit; b is the slope of the regression; D0 is 
the dose, D, value to be determined and Dmean is the 
mean of the D values of all calibration point Di. 
Performance parameters and predicted uncertainty 
In the framework of the European Research project 
Southern Urals Radiation Risk Research (SOUL, 
2005), a benchmark protocol was established between 
three EPR laboratories (HMGU, Munich, ISS, Rome, 
and IMP, Ekaterinburg) for the definition of the 
performance parameters for EPR dosimetry with tooth 
enamel and for the prediction of associated 
uncertainty96. The parameters critical dose and limit of 
detection, taken from chemical metrology97,98 were 
deemed to be most appropriate to characterise the 
uncertainty of EPR measurements.  
The definition of critical dose follows from the 
hypothesis test for 95% probability of an unirradiated 
sample and hence allows a false positive error rate, , 
of 5%. In other words, within the distribution of 
measured EPR signal amplitudes from unexposed 
samples, there is an accepted probability of 5% that the 
amplitude is larger than the critical amplitude, which is 
the decision limit below which it is assumed that the 
sample was not exposed and above which it is assumed 
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corresponding to the critical amplitude on the EPR 
signal-to-dose response curve is then termed the 
critical dose. 
The definition of the limit of detection follows from 
the hypothesis test for 95% probability that the sample 
was exposed, hence allowing for a false negative error 
rate  of 5% indicating that an exposure did not occur. 
That is, within the distribution of the measured EPR 
signal amplitudes from exposed samples, there is 
probability  of 5% that the amplitude is lower than the 
critical amplitude. A graphical illustration of the 
definitions of critical amplitude and limit of detection 
is shown in Figure 1. 
 
<Figure 1 here> 
Figure 1. A graphical illustration of the definitions of critical 
amplitude (ICL) and critical dose (DCL), limit of detection of 
signal amplitude (IDL) and of absorbed dose (DDL). (Figure 
adapted from 96). 
 
The critical amplitude, ICL, and the limit of 
detection, IDL, of EPR signal intensity are calculated 
from the mean of measurements of unexposed samples 
(b0) and the estimated standard deviation of n EPR 
measurements of unexposed samples,    , and samples 
exposed to a dose DDL.     , respectively: 
 
                      (14) 
 
                        (15) 
 
The estimated standard deviation must be multiplied 
by the Student’s critical value t(1−[α or β],n−2), the (1-[α or 
β]) percentage point of Student’s t distribution with the 
single-sided confidence interval chosen according to 
the desired confidence level (1-[α or β]) and number of 
samples n. The standard deviations may be evaluated 
from the 90% prediction bands of an unweighted linear 
least-squares fit of the EPR signal-to-dose response 
curves in the case of constant uncertainty. 
Alternatively, in the case of dose dependent 
uncertainty, the values of the standard deviations may 
be predicted from an analytical model function 
formulated from the variance of EPR measurements on 
the absorbed dose. An example function of variance as 
a function of absorbed dose in tooth enamel, developed 
at the EPR laboratory of the ISS, is reported in Figure 
2. 
Following work carried out under the European 
project SOUL, the benchmark protocol has been used 
for the estimation of the performance parameters 
within several EPR dosimetry method 
intercomparisons13,99.  
<Figure 2 here> 
Figure 2. Model function of variance as a function of the EPR 
signal amplitude in tooth enamel, built at the EPR laboratory 
of the ISS. 
OSL/TL 
Evaluation of uncertainties  
In OSL and TL, there is no specific standard dedicated 
to the evaluation of uncertainties, and evaluations 
normally follow the classical GUM21 guidance.  
Uncertainty analysis is performed using the standard 
theory of error propagation. If only a single dose 
calibration point is used then the unknown absorbed 
dose, DX, is obtained through a simple comparison 
between the corresponding luminescent signal (TL or 
OSL) and the luminescent signal,     , obtained after 
exposing the same dosemeter to a calibration dose Dcal. 
If fading is an issue then either the signal or the 
measured dose can be corrected for this effect. 
Two cases will be considered here, both of which 
have been applied in the literature: 1) the fading factor 
is determined individually for the sample in question 
using the (known) time tX since irradiation and 2) the 
fading factor is calculated based on a known fading 
function, with associated uncertainties. 
In the case of 1), a possible approach would be as 
follows: after measurement of the signal IX related to 
the unknown dose DX of the incident, with a time delay 
tX since this incident, the sample is given a calibration 
dose Dcal and a corresponding signal Ical is measured 
after a time tcal. The latter procedure is then repeated 
with the same dose Dcal but this time waiting for a 
longer time interval tX (the same time delay as for the 
accidental exposure), before measuring the 
corresponding signal IX,Dcal. The fading factor is then 
directly determined by the simple relation: 
 
  
      
    
  (16) 
 
In this case, only the measurement uncertainties of 
IX,Dcal and IX are required for evaluation of the 
uncertainty in f. The unknown absorbed dose DX is then 
calculated as:  
 
   
  
      
     , (17) 
 
with IX being, as above, the signal measured after the 
unknown exposure, with a delay time tX. It is important 
to note the difference between IX and IX,Dcal. Equation 
17 can then be simplified to: 
 
AINSBURY ET AL 
12 
   
  
      
       (18) 
 
Therefore only the measurement uncertainties in IX 
and IX,Dcal and the uncertainty in determining Dcal are 
needed for the calculation of uncertainty in DX, which 
can be carried out using the GUM methodology as 
explained in the above sections.  
This method assumes that the uncertainties in IX and 
IX,Dcal exhaustively explain the observed deviances in 
the dose-response and fading curves. However, from 
experience, it is known that this is probably not always 
the case and the uncertainty in DX is therefore likely to 
be underestimated using the above procedure. For 
instance, an uncertainty in the time tX since the 
unknown exposure is not considered.  
In the case of 2), fading is calculated according to a 
functional relationship fitted to datasets of other 
samples. For chip cards and electronic components, 
where the effect of anomalous fading is suspected, this 
functional relationship between intensity and time since 
irradiation is well-known69,100–104: 
 
              
 
  
   (19) 
 
With IC being the signal intensity that would be 
observed after an (arbitrarily) chosen time tC after 
irradiation and  a fitting constant (in the literature, the 
common logarithm is often used and  replaced by 
g/100, with g being the percentage decrease per 
decade). If, for convenience, tC is set to tcal before 




     
       
         
  
    
    (20) 
 
The difference between equations (20) and (16) is 
that here the signal intensities are calculated rather than 
measured. If, again, a single calibration dose is used to 
convert signal to dose, the unknown dose DX is 
calculated according to equation (17). If uncertainties 
are assumed in , tX, tcal, IX, Ical and Dcal, then in this 
simplified case, the uncertainty in DX can be assessed 
using GUM methodology: 
 
         
     









     














      
  
    
  
 
   





   
   
 
    
 
 
     
  (22) 
 
It should be emphasised that if published fading 
parameters in equation (19) are used and tC does not 
equal tcal, then equation (20) should be applied in its 
more general form, as a ratio of two calculated 
intensities with associated uncertainties. The 
calculation of the uncertainty in DX is then more 
laborious but still straightforward. Another issue is that 
if equation (19) is fitted to fading data obtained from 
averaged signals of several samples, which is 
sometimes done, then the calculated signal uncertainty 
will always be lower than the standard deviation of the 
input data, i.e. the uncertainties in the parameter  and 
IC are unlikely to describe the full variability in 
observed fading behaviour. One possibility to 
circumvent this issue is to fit the fading data of each 
sample individually, rather than to average signals and 
then to calculate average and standard deviation of the 
group of obtained parameter values. This approach has 
e.g. been pursued in the MULTIBIODOSE project49.  
For a luminescence reader with a built-in calibration 
source, the time delay tcal between irradiation with the 
calibration dose and measurement is usually known 
very accurately, therefore the uncertainty cal can be 
neglected in this case. On the other hand, an increase in 
the value of tcal leads to a reduction in the first term in 
equation (22) and thus to a reduction in the uncertainty 
of the fading factor. Furthermore, there will also be 
fading during the irradiation period itself, i.e. during 
tirr. If tcal is of the order of tirr this should be accounted 
for in evaluation of the uncertainty in Dx, for example 
(approximately) by adding tirr/2 or tirr/ln2 to the delay 
time. It is more correct, however, to make tcal >> tirr. 
It should be noted that, in general, the fading 
function that is appropriate to the materials being 
studied should be determined independently and the 
uncertainty analysis appropriate to that expression 
should then be evaluated and used. As an example, in 
case of human teeth as well as integrated circuits from 
mobile phones, the fading curves were better fitted by a 
bi-exponential decay function100,102. In contrast to 
electronic components, sensitive dosemeter materials 
with comparatively slow or no fading, such as 
household salt (NaCl)101,105 and quartz extracted from 
building materials106–108. The application of 
retrospective luminescence dosimetry in areas affected 
by fallout from the Semipalatinsk nuclear test site: an 
evaluation of potential. Health Phys 87(6):625–664), 
may have a substantial background signal if shielded 
from light during the time of storage before irradiation. 
The detection limit in such materials is related to the 
magnitude and the uncertainty in the background 
signal. The background absorbed dose in for example 
household salt may vary depending on how the salt was 
manufactured101, in what package it was kept, and how 
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and where this package was stored105. For quartz 
extracted from bricks, the background dose depends on 
the concentration of natural radionuclides in brick, 
plaster and soil in front of the building and on the age 
of the bricks (same references as above). In these cases, 
when the dose is in the region of the background dose, 
the variance in the background dose will predominate 
over the uncertainty in the dose measurement itself.  
However, for higher doses, in the region of several 100 
mGy or above, the uncertainty in background dose will 
have a lesser impact.  
Luminescence signals as recorded by photon 
counting hardware are in essence a binomial signal, 
which is supposed to approximate the Poisson-
distribution when sufficient counts are registered. In 
OSL, a background is usually subtracted from the 
measured signal, determined from a certain part of the 
OSL decay curve (often the last seconds of the 
measured signal). The background can be a 
combination of hard-to-bleach components and 
instrumental background and as such can be over-
dispersed. Detailed approaches for the calculation of 
uncertainty for the net OSL count in such a case can be 
found in the literature, e.g.109.  
If several calibration doses are used in order to 
verify the dose-response curve, or several delay times 
are used to verify the fading curve, a number of 
different methods are applied. These include 
proprietary codes or spreadsheets, software for 
luminescence data processing (e.g. Analyst110), or 
dedicated curve fitting packages (e.g. Sigmaplot111, 
Origin112). The equations chosen to approximate dose 
responses are commonly linear, saturating exponential 
(sublinear), or exponential/quadratic (superlinear) in 
form113.  
If a sample is divided into several aliquots to assess 
  , the quantities    and      could be calculated as the 
average of the luminescent signals of the different 
aliquots and their uncertainty as the weighted standard 
error of the mean. However, to avoid additional 
uncertainties due to the different aliquot sensitivities, in 
practice, a dose is usually measured for each aliquot 
individually and the obtained distribution in aliquot 
doses further analysed to obtain a best estimate and 
uncertainty for   . 
A variety of approaches has been developed for 
obtaining central measures from non-perfect data in 
this case28,114,115. Means and maximum likelihood 
estimates such as the weighted mean (weighted to 
inverse variance) are associated with well-defined 
uncertainty estimates21, which are obtained by 
propagation of uncertainties through calculation 
(internal error) or by evaluation of dispersion in the 
observed results (external error). Dispersion in 
observations is commonly observed to be greater than 
that predicted by propagation of uncertainties through 
the calculation of the central estimate, leading to the 
term “over-dispersion”. This can relate to experimental 
variables that are undefined or not included in the 
calculation, and where signal levels are low. It may 
also relate to the assumptions underlying the 
calculations themselves. The combination of data in 
GUM based approaches assumes a Gaussian 
approximation of the Poisson distribution.  
 
 
MONTE CARLO MODELLING TO SUPPORT 
UNCERTAINTY CALCULATIONS 
A key aim of the EURADOS WG 10 uncertainties task 
is to further promote the powerful Monte Carlo (MC)  
techniques for uncertainty estimation. Thus, in addition 
to the above, we present the following review of use of 
MC methods within uncertainty estimation. With the 
availability of high-power computational facilities, 
numerical simulations have become increasingly 
practical and popular for analysis of physical or 
biological systems. One method of numerical 
simulation that has widespread application in 
dosimetry, as well as in countless other physical and 
biological sciences, is the Monte Carlo method.  
MC modelling can be used to aid and analyse 
uncertainty propagation, where the goal is to determine 
how random variation, lack of knowledge, or error 
affects the sensitivity, performance, or reliability of the 
system that is being modelled. However, this inevitably 
comes at a cost: the MC method is itself prone to 
uncertainty, and can therefore also be an additional 
source of error. The current section of this paper 
focuses on two applications of the Monte Carlo method 
that are relevant to retrospective dosimetry. The first 
application discusses the use of Monte Carlo programs 
created specifically for uncertainty propagation 
analysis, giving an illustrative example of the 
technique. The second application concerns the MC 
transport of ionising radiation through matter, which is 
a common technique used to model retrospective 
dosimetry systems. In each case, the role that MC plays 
in both increasing and decreasing a user’s 
understanding of uncertainty is discussed. 
Uncertainty propagation with Monte Carlo 
Monte Carlo Simulation (MCS) provides a practical 
alternative to the GUM modelling approach. Indeed, 
the GUM method has limitations, especially in the case 
in which the model is characterised by a nonlinear 
function and the approximation of a Taylor’s series 
expansion up to first-order terms for error propagation 
is not good enough. Furthermore, the uncertainty 
distributions may be non-Gaussian and is not always 
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possible to propagate uncertainties using the GUM 
approach 21,116–120. The use of MCS for the evaluation 
of measurement uncertainty is presented by the “GUM 
Supplement”21. MCS may be applied to estimate the 
combined effects of uncertainty propagation through a 
physical system that comprises a number of individual 
components, each of which possesses outcomes and 
uncertainties expressed by independent probability 
functions. Many authors report applications of MCS for 
determination of their measurement uncertainties: 
Couto et al.116, for example, recommended its use for 
complex problems that could not be solved by the 
GUM method. Whereas GUM calculations are purely 
theoretical, MC analyses aim to perform a large series 
of simulated experiments, with estimates of 
uncertainties then derived by considering the 
distributions of their results. In most simple cases, the 
theoretical GUM results can be compared and tested 
experimentally against the MC ones. In more 
complicated situations where the GUM approach 
would be difficult or unfeasible, MC simulations may 
still easily provide reliable results. Moreover, whereas 
the GUM modelling approach may require advanced 
mathematical skills for many of its procedures, the 
MCS method can be applied more easily using readily 
available spreadsheet software, such as Microsoft(R) 
Excel(R) or Libreoffice Calc: complex uncertainty 
calculations can hence be accomplished by standard 
spreadsheet applications rather than by technically 
demanding mathematical procedures119,120. 
The MCS method for assessing uncertainty 
propagation  
MC analyses require the definition of a measurement 
model (with the corresponding functional relationship) 
that describes the measurement process in terms of the 
inputs to the measurand and the assessment of the types 
of distribution that apply to the various input 
uncertainties. The aim of the MC analysis is then to 
obtain properties of the measurand quantity, Y, such as 
expectations, variances and covariances, and coverage 
regions, by calculating an approximate numerical 
representation of the distribution function GY for Y. 
Suppose that Y is function of various independent 
variables Xi, i.e. Y=f(X)=f(X1,....,XN) with i from 1 to N; 
for the present discussion, the Xi are assumed to be 
continuous parameters, but similar techniques can be 
used for discrete variables. For each input variable Xi 
the corresponding probability density function (PDF), 
P(Xi), describing its likely values is assumed to be 
known. A value for Y may therefore be drawn by 
sampling the N input quantities Xi from their respective 
PDFs. In practice, this sampling procedure is typically 
achieved computationally using pseudo-random 
numbers that are generated algorithmically according 
to a uniform distribution between 0 and 1, and then 
suitably “transformed” to obtain the prescribed 
probability distribution. One such transformation 
makes use of the cumulative distribution function 
(CDF), C(Xi), corresponding to a given P(Xi), which is 
a monotonically increasing, normalizable function with 
a range constrained between 0 and 1; the result from 
the MC sampling of the uniform distribution may be 
identified with a value within the range of this CDF, 
which then maps uniquely to a specific outcome Xi. 
The commonest distributions, P(Xi), used in 
uncertainty calculations are Gaussian, rectangular, 
triangular, t, exponential, gamma and multivariate 
Gaussian; it is possible to sample fairly from each of 
these distributions by using a uniform distribution 
between 0 and 1 that is randomly sampled by Monte 
Carlo methods.  
Sampling once from each of the N PDFs, P(Xi), 
corresponding to the N independent input quantities Xi 
provides one value for the measurand, which may be 
labelled Y1, by using the expression of the f(X) 
function. Clearly, the value of Y1 will depend on the 
specific outcomes that were obtained during the N 
random samplings, and repeating the process is likely 
to yield a different estimate, i.e. Y2. If the MCS is 
repeated M times, requiring MN samplings overall, a 
distribution, GY, of M values for the measurand are 
generated, i.e. {Y1, Y2,…, YM}. This process is repeated 
a sufficiently large number of times (i.e. M is very 
large) in order to have significant statistics, i.e. until it 
may be assumed that the generated distribution GY 
provides a reasonable estimate of the likely distribution 
of the true measurand, Y. Since the input values are 
randomly drawn from the predefined probability 
distributions associated with each of the input 
variables, the information regarding these PDFs will be 
included implicitly in the distribution of the Y variable, 
and this allows for the propagation of distributions. 
Once the representation GY of the distribution 
function for Y has been derived, it is possible to extract 
from it values for the mean and standard deviation 
associated with Y as well as the other moments of the 
distribution function. Moreover, the distribution of 
output data can be plotted and additional information 
can be extracted from that graph, such as the coverage 
interval of the measurand for a stipulated coverage 
probability, p, even when the PDF of the measurand 
has significant asymmetry. The possibility of graphical 
representation of the distribution of the measurand 
through the MCS procedure allows for the 
individuation of possible asymmetry or deviation from 
Gaussian shape. This graphical representation favours 
the determination of a coverage interval corresponding 
to a stipulated coverage probability. 
From the above discussion, the advantages of MC 
simulation with respect to the GUM approach21 are 
RETROSPECTIVE DOSIMERTY UNCERTAINTIES 
15 
seen to be manifold. The MC technique involves 
propagation of distributions and always provides a PDF 
for the output quantity that is consistent with the PDFs 
of the various inputs, whereas the GUM modelling 
approach is not able to explicitly determine a PDF for 
the output quantity. Also, in the case in which the input 
quantities may themselves depend on other quantities, 
including corrections and correction factors for type B 
errors, MCS is able to calculate the combined standard 
uncertainty of the measurand, even if the functional 
relationships are complex or difficult to deal with 
analytically. Similarly, if two inputs are correlated via a 
bivariate distribution, MC analysis can provide a joint 
simulation if the input PDFs are defined in such a way 
to include the correlation coefficient. Additionally, the 
MCS procedure intrinsically accounts for any non-
linearity in the functional relationship, whereas GUM 
does not; in general, more accurate estimates of 
uncertainties for non-linear models are therefore 
achieved through MC calculations. 
Application of the MCS method for uncertainty 
propagation  
In order to show how the MC method is used to 
evaluate measurement uncertainties, an example 
application for electron paramagnetic resonance (EPR) 
retrospective dosimetry is reported here. Consider a 
plot of EPR signal as a function of absorbed dose, and 
assume that the data may be fitted with a calibration 
curve characterised by a quadratic trend. This 
behaviour is common for samples that present a 
background signal that is of the same shape and 
overlaps the signal induced by irradiation; in these 
cases the exposure to ionising radiation produces an 
increase of EPR intensity of these signals. An example 
of such a calibration curve is shown in Figure 3. 
<Figure 3 here> 
Figure 3: Example of quadratic calibration curve of EPR 
signal vs. absorbed dose. 
The expression for the fitting function in this case is 
of the general form: 
 
S = a + b×D + c×D2  (23) 
 
where S is the EPR signal, D is the absorbed dose 
and a, b and c are the fitting parameters of the 
calibration curve, which in this example have the 
values a = 10.4 ± 0.2, b = 1.527 ± 0.011 and c = 
0.409 ± 0.005. 
In EPR retrospective dosimetry, the general 
approach is to reconstruct the absorbed dose Dr 
deposited during an exposure from a measurement of 
the induced signal, with corrections applied to account 
for fading and other measurement conditions. Suppose 
that, as per equation (7) s is the signal measured from a 
sample, and that the corresponding standard deviation 
σED is calculated by considering the various 
contributions from the standard deviations associated 
with the fading correction (σF), the sample preparation 
process (σS), the EPR measurement (σE), and from the 
numerical treatment of spectra (σT). For the present 
example, suppose that s ± σED have the values 25.5 ± 
0.7. The reconstructed dose can be calculated by 
inverting Equation 23, i.e.: 
  
  
              
  
        (24) 
 
As can be seen, equation (24) contains a fraction and 
a square root term. The calculation of the standard 
deviation, σD, of the reconstructed dose following the 
GUM modelling approach is therefore not 
straightforward because, to take into account the 
uncertainties of the calibration curve parameters, the 
corresponding partial derivatives of the factors in 
equation (24) should be calculated. In fact, under the 
simplifying hypothesis that the covariances between 
the various fitting coefficients are negligible, this 
uncertainty becomes analogous to equation (8): 
 

























  (25) 
 
After the calculation of the partial derivatives and 
the substitution of the above-mentioned values, this 
approach can be shown to provide the result Dr = 
4.49 ± 0.14 Gy. 
On the other hand, this calculation can be performed 
by MCS following an easy procedure with common 
spreadsheet software. An example of this MC analysis 
is reported in Figure 4. In Figure 4, the values in the A, 
B, C and D columns are realizations of the s 
measurement and the a, b and c parameters, 
respectively. All of these quantities are assumed to be 
distributed normally around their respective average 
values with their respective standard deviations, which 
are stated at the top of Figure 4. Based on these 
distributions, trial values are drawn for each of the 
input variables (a, b, c and s), and the corresponding 
value of the dose D (column H) is then calculated using 
equation (24). In this example spreadsheet, the values 
were calculated by using a combination of the 
NORMINV (for calculating Gaussian-distributed 
values) and RAND (for generating pseudorandom 
values) functions, according to the procedure described 
in the literature120. Figure 4 lists the results from ten 
such applications of this process; for the complete 
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analysis, a total of 106 trials were performed. A 
histogram of the dose values obtained from these 106 
trials is reported in Figure 5 binned in 0.02 Gy 
increments, with the probability (y-axis) derived from a 
normalization of their respective populations. 
 
<Figure 4 here> 
Figure 4: Example of a Monte Carlo simulation for estimating 
the uncertainty of an EPR measurement, performed using a 
spreadsheet program. 
<Figure 5 here> 
 
Figure 5: Histogram of dose values obtained by means of 
Monte Carlo simulations. 
The mean value and the standard deviation of the 
results are readily calculated from the histogram 
(Figure 5), and can be shown to be equal to 4.49 Gy 
and 0.14 Gy, respectively, in this example. These 
values are consistent with those obtained by the GUM 
approach. However, as mentioned previously an 
advantage of the Monte Carlo analysis is that it also 
provides the PDF for the output quantity, which is 
dependent on the PDFs of the various inputs. Other 
moments of the distribution can also be obtained from 
this PDF, such as the skewness and the kurtosis. These 
are found to be -0.0588 and 3.0093 respectively for the 
data in the current example (Figure 5), which are 
similar to the values of 0 (skewness) and 3 (kurtosis) 
for a Gaussian distribution, as expected since the PDFs 
of the input variables were all assumed to be Gaussian-
like. 
Another application of the Monte Carlo technique is 
the uncertainty analysis for TL measurements on 
display glass of mobile phones. The absorbed dose 
measurement is influenced in this case by the presence 
of an intrinsic background signal and signal fading103. 
The intrinsic background signal can be reduced by 
etching the glass sample in concentrated HF before 
measurement but not completely eliminated104. In both 
cases (etched or unetched), the distribution of intrinsic 
background doses could be shown to approximately 
follow a log-normal distribution. From the measured 
dose D, along with its estimated uncertainty D, the 
corrected unknown absorbed dose Dcorr is then 
calculated from the expression: 
 
      





 being the median of the intrinsic 
background dose distribution and f the fading factor. 
Analysis of the signal fading of 17 different glass 
samples for different storage times indicated that the 
variability (standard deviation) in f is approximately 
independent of the value of f itself, therefore a constant 
value for f is assumed.  
Since the calculation of uncertainty for the corrected 
dose involves the combination of Gaussian and non-
symmetrically distributed parameters, the GUM 
methodology is not directly applicable whereas with 
the MCS the simulated distribution of possible 
corrected dose values is easily obtainable, allowing the 
immediate assessment of the median and the 95% 
confidence interval. An example for two unetched glass 
samples from mobile phones is shown in Fig. 5. For the 
sample with the lower dose the uncertainty in the 
intrinsic background dose dominates, leading to a 
distribution skewed to the left whereas for the sample 
with the higher dose, the uncertainty in the fading 
dominates, leading to a distribution skewed to the right.  
 
<Figure 6here> 
Figure 6: Histogram of dose values for two display glass 
samples of irradiated mobile phones (Samsung Galaxy Y 
S5360). Nominal doses were 0.6 Gy and 1.5 Gy, reconstructed 
doses with 95% CI, 0.59 [0.18-0.83] Gy and 1.6 [1.3 -2.2] Gy, 
respectively. 
Radiation transport modelling with Monte Carlo 
There are a number of Monte Carlo radiation transport 
codes currently available, examples including the 
EGSnrc121, FLUKA122, GEANT123, MCNP124, 
PENELOPE125 and PHITS126 families of software. 
These codes are described as “general purpose”: they 
are intended, in principle, to be able to model the 
passage of any type of ionising radiation from any type 
of source through any arrangement of matter that might 
be required by their users, providing output data on 
parameters such as energy depositions and fluences at 
any location of interest in the geometry. Accordingly, 
these codes have widespread application in 
retrospective dosimetry127–133, where computer models 
of the dosimetry system in question may be created and 
interrogated to understand or improve its performance, 
limitations and uncertainties. Despite these successes, 
however, the techniques are not without drawback: 
although they may be a valuable tool in evaluating and 
handling uncertainty, they may also be a source of this.  
Statistical uncertainties with MC modelling 
It is relatively easy for the users of general purpose 
MC codes to reduce the statistical uncertainties on their 
results. Essentially, these procedures typically rely on 
increasing the number of scored histories in the regions 
of interest within the geometry. The most elementary 
such method is simply to instruct the program to 
simulate the histories of a greater number of particles, 
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though inevitably this is achieved at the expense of an 
increased CPU time. More sophisticated techniques of 
variation reduction can also often be implemented, 
such as biasing source directions, forcing particular 
interactions to occur, or artificially splitting individual 
particle histories into multiplicities for example, with 
scores then having to be weighted accordingly to 
ensure fairness and fidelity of results. Using these 
techniques, and coupled with the power of modern 
computers (especially cluster-based platforms), it is 
therefore not uncommon for simulated results to be 
associated with very small statistical uncertainties, 
sometimes a fraction of a per cent. But anecdotally, at 
least within the experience of the authors of this current 
article, such values are often then quoted in the 
scientific literature as the primary or only uncertainty 
that is provided with a particular Monte Carlo result. 
This is misleading, however, because it neglects the 
type B uncertainties that are also inevitably associated 
with the modelling, which tend to be much harder to 
quantify and may be substantially larger in magnitude. 
Paraphrasing, with Monte Carlo modelling it is often 
easy to derive highly precise results, but this does not 
necessarily mean that they are accurate; arguably, the 
important difference between these two qualities is not 
always granted enough weight. 
Known type B “systematic” uncertainties 
The MC radiation transport method simulates the 
passage of particles through a user-defined 
configuration of matter. Accordingly, the accuracy with 
which the computational model reflects physical reality 
will dictate the accuracy of its results. Clearly, then, 
there are a number of factors that could introduce 
significant uncertainty into the modelling. These might 
be classified into two broad types: uncertainties 
inherent in the Monte Carlo software; and uncertainties 
associated with the user-defined model itself. 
Type B uncertainties within the Monte Carlo 
software incorporate factors such as uncertainties in the 
underlying physics upon which it relies. These 
uncertainties include, for example, limitations and 
inaccuracies of the interaction models that might be in 
use, including any energy-dependencies that they might 
have. Although many of these uncertainties may be 
known in principle, or could be derived from the 
various references that describe the origins of the 
physical data and models underpinning the general 
purpose codes, their magnitudes may not be readily 
apparent to “casual” users of the software, with their 
combined effects even harder to quantify. Their 
contributions to the overall uncertainty budgets arising 
from the use of Monte Carlo modelling in retrospective 
dosimetry are therefore highly context dependent, and 
difficult to numerate in general. 
Type B uncertainties that originate from the users of 
codes reflect the inevitable inability of these users to 
construct a perfect model of the physical system. This 
failure might be because of factors that can only be 
known with limited resolution, and can hence only be 
input to the MC program with limited accuracy. To 
give an illustrative example, in the modelling of 
resistors in mobile phones for fortuitous dosimetry132, 
the absorbed doses received by the target will depend 
strongly on accurate knowledge of the material 
compositions and densities of the aluminium oxide 
substrate, the high-Z contact electrodes adjacent to it, 
the circuit board to which it is attached, and the screen, 
case, battery and other features that surround it, as well 
as on all of their relative locations in 3D space; the 
estimates of each of these physical parameters will be 
subject to a significant measurement uncertainty, and 
this is translated into an unavoidable inaccuracy of the 
MC model (and hence its results). 
Some type B uncertainties may be mitigated by 
performing sensitivity analyses with the model. In fact, 
investigating the likely effects of such sensitivities in 
the physical world might be the primary motivation for 
developing the Monte Carlo model in the first instance. 
For example, the impact on dosimetry of the 
measurement uncertainty on the density of a given 
object in the real world may be estimated by perturbing 
the density of that object in the model by an amount 
deemed equivalent to that uncertainty, and then 
repeating the simulation; comparison of the perturbed 
and unperturbed results provides an estimate of the 
effects of that density uncertainty. Similarly, by 
varying the concentration of crucial elements, the same 
approach may be used to estimate the impact of 
uncertainty regarding the material composition128. The 
MC method is thus seen to be a quick and effective 
means of quantifying the effects of a given uncertainty 
in a physical system. 
The above univariate sensitivity analysis may be 
generalised to account for error propagation and the 
overall uncertainty budget. Specifically, uncertainty 
propagation analyses can be achieved by repeating the 
sensitivity analysis for all parameters within the 
physical model that are associated with a significant 
type B uncertainty. In fact, this procedure may be 
applied to assess the impacts of both the physical 
uncertainties (i.e. the measurement uncertainties) and 
the code-specific ones; this latter assessment might be 
achieved by rerunning the simulation using different 
simulation parameters, for example choosing 
alternative cross-section databases or interaction 
models. Overall, the procedure therefore leads to 
distributions of perturbed data around a mean, which 
may be interrogated by standard techniques to obtain a 
handle on the overall quality of the quoted result, and 
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hence on the robustness of its predictions about the 
performance of the physical system being modelled. 
Unknown type B “systematic” uncertainties 
In addition to applying Monte Carlo techniques to 
estimate the effects of known type B uncertainties in a 
physical dosimetry system, such as uncertainties on the 
precise material composition of a dosemeter, it is also 
possible to use them to estimate the effects of unknown 
type B uncertainties. Unknown type B uncertainties 
include those factors that will affect the results 
recorded by a retrospective dosemeter, but are a 
consequence of ignorance of the values of key 
parameters rather than any imprecision in the estimates 
of them; these could include uncertainties resulting 
from incomplete knowledge of the nature of the 
exposure conditions of the dosemeter, for instance, or 
missing data on the characteristics of the source term. 
An example of this might be a situation in which it 
acknowledged that an energy-dependent correction to 
the response of a dosemeter needs to be made, but 
when the energy of the radiation source to which it was 
exposed is not known. In such cases, it might be 
appropriate to use Monte Carlo techniques to model the 
responses of the dosemeter to a range of plausible 
sources with different energies, with the subsequent 
variation in the results then used to provide a handle on 
the maximum error that is likely to be caused by the 
ignorance of the true energy of the physical exposure. 
As an illustrative case study of the application of 
MC in handling this type of uncertainty, consider the 
use of mobile phones as emergency retrospective 
dosemeters. Although phones, or more specifically 
their display screens or resistors, possess many of the 
features considered advantageous to act as reliable 
fortuitous dosemeters, for them to be useful it is 
mandatory to relate the absorbed doses they record in 
an exposure to the concurrent doses deposited in their 
owners. This can be achieved by Monte Carlo 
modelling of the phones located at various positions on 
an anthropomorphic phantom, exposing the 
configuration to various fields, and then comparing the 
doses deposited in the phones and phantom to generate 
a set of exposure- and location-dependent conversion 
factors; for some locations and exposures, phone and 
body absorbed doses may differ by a factor of ~20129. 
In the real world, however, the precise location of the 
phone relative to the body during an unplanned 
exposure may not be known in hindsight, at least not to 
those performing the dosimetry. Moreover the precise 
exposure conditions, and orientation of the individual 
relative to the source, are also unlikely to be recorded. 
Accordingly, this ignorance introduces a significant 
unknown type B uncertainty into the conversion of 
phone doses to body doses. But, this ignorance may be 
managed by the use of mean conversion factors that are 
averaged over the datasets of all of the parameters that 
are unknown. For instance, if the exposure geometry 
and radiation source were known with some degree of 
confidence, this averaging might just be over the 
conversion factor datasets generated by the Monte 
Carlo model for the different phone positions; but if 
only the source were known, then the averaging would 
be over the datasets for all phone positions and all 
exposure geometries. Use of these mean conversion 
factors is then associated with conservative 
uncertainties identified as the maximum over- and 
under-responses that are expected to arise from their 
application. These extrema may be taken from the 
envelope function of the conversion factors that were 
summed-over in the averaging process, and quantify 
the worst-case errors in the dosimetry that might be 
anticipated in adopting this conversion process due to 
the unknown type B uncertainty in the exposure 
conditions. This is an important separate topic for 
further consideration. 
BRIEF DISCUSSION AND CONCLUSIONS 
In this paper, the current state of the art in terms of 
uncertainty analysis techniques for biological 
dosimetry (with the DCA as the most well developed 
example) and physical retrospective dosimetry has 
been reviewed, with a particular emphasis on the 
potential for increased use of the more sophisticated 
Bayesian and Monte Carlo modelling methodologies to 
support uncertainty characterization.  
To survey the current situation, a questionnaire was 
compiled and sent to all members of EURADOS 
WG10 on retrospective dosimetry. The questionnaire 
was designed to gather information on current 
experience on uncertainties estimation but also to 
assess the possible needs in terms of training or 
courses. From the 28 laboratories who responded, 72% 
currently use physical retrospective dosimetry 
techniques (EPR, TL and OSL), 19% biological 
techniques (micronuclei, dicentrics, FISH, and γ-H2AX 
and 8% others techniques (UV-vis spectroscopy, 
neutron activation, etc.). 56% of the responders use 
only the classical GUM approach, 13% the approach 
described in the IAEA manual for cytogenetics, about 
18% Monte Carlo method and about 9% uses a partial 
Bayesian approach. None of the responders used a 
formal Bayesian approach. It is interesting to note that 
56% of responders use software to calculate the 
uncertainties (35% in house-developed software, 41% 
commercial software and 24% freely available 
software). 64% of responders are satisfied with their 
method, but would be interested in improving it and/or 
to evaluate and compare other approach such Bayesian 
or MC methods, whereas 24% are aware of the 
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weakness of their approach or think they may use an 
inappropriate one. 
So, in general the situation looks positive for the 
most well-established assays, with practical, accepted 
analysis techniques in place (chiefly based on GUM) 
which likely support good overall absorbed dose and 
uncertainty estimates. The exception is for the more 
complex exposure scenarios19, which are known to 
introduce additional uncertainties which should ideally 
be characterised on a case-by-case basis. The tools to 
do this are in place (for instance in the GUM21) but, in 
practice, are not often applied for biological dose 
estimation, and to date physical retrospective dosimetry 
techniques have only really been used for a set of 
“standard” scenarios. Thus there is still work to do. 
The next steps in development of uncertainty 
analysis techniques across the field of retrospective 
dosimetry will be to look at standardization of 
techniques – i.e. to evaluate which of the methods 
detailed in this work give the most accurate 
representation of uncertainty in various different 
exposure scenarios, including the more difficult cases. 
In addition, as discussed, uncertainty analysis is a 
complex field in itself and thus an “expert” level of 
knowledge is required. For example, the application of 
GUM can be very complex and long, especially when 
the different terms of uncertainties are correlated (cf. 
calculation of covariance terms). In many 
circumstances GUM also requires approximation, and 
the situation is further complicated when the 
mathematical model that fits the relation between input 
data (measurand) and output data (dose) is anything 
other than linear. The estimation of each of the 
uncertainty term may need a large amount of work 
(including experimental work). In light of this, MC or 
Bayesian approaches would be particularly efficient for 
retrospective dosimetry application. However, to date, 
only a small number of EURADOS retrospective 
dosimetry Group members use these methods, and 
further work is required. For example, for GUM the 
algebraic benefits of using the Gaussian approximation 
should be balanced against its potential divergence 
from the “true” uncertainty of the observations. 
However, the way in which the uncertainty is 
characterised at each stage in a Monte Carlo calculation 
should be appropriate to the observations and/or should 
allow for uncertainty in its own assignment28, and the 
extra analytical power provided by the use of Bayesian 
priors requires that their presence and form be carefully 
justified in order to limit the potential for 
mistakes26,31,134. In addition, it is worth noting that 
beside retrospective dosimetry, EPR has long been 
used for metrology with for instance alanine and 
recently with tartrates and formats135,136. In this field 
comparatively large amount of effort has ensured that 
the uncertainty analysis supports highly accurate 
absorbed dose determinations137. However, these 
principles are equally useful for retrospective 
dosimetry even if the intrinsic uncertainties are larger 
and thus the accuracy normally is lower in this case.  
It will thus be very important for researchers active 
in these fields to ensure that new methods are 
disseminated and that new and existing colleagues 
access appropriate training. This is something that 
EURADOS WG10 will continue to support going 
forward. 
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